"CD56 Antigen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The 140 kDa isoform of NCAM (neural cell adhesion molecule) containing a transmembrane domain and short cytoplasmic tail. It is expressed by all lymphocytes mediating non-MHC restricted cytotoxicity and is present on some neural tissues and tumors.
| Descriptor ID |
D019002
|
| MeSH Number(s) |
D12.776.395.550.200.250.520.156 D12.776.543.550.200.250.520.156 D23.050.301.264.894.156 D23.050.301.350.250.520.156 D23.101.100.894.156
|
| Concept/Terms |
CD56 Antigen- CD56 Antigen
- Antigen, CD56
- Leu-19 Antigen
- Antigen, Leu-19
- Leu 19 Antigen
- Antigens, CD56
- NKH-1 Antigen
- Antigen, NKH-1
- NKH 1 Antigen
- CD56 Antigens
|
Below are MeSH descriptors whose meaning is more general than "CD56 Antigen".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Glycoproteins [D12.776.395]
- Membrane Glycoproteins [D12.776.395.550]
- Cell Adhesion Molecules [D12.776.395.550.200]
- Cell Adhesion Molecules, Neuronal [D12.776.395.550.200.250]
- Neural Cell Adhesion Molecules [D12.776.395.550.200.250.520]
- CD56 Antigen [D12.776.395.550.200.250.520.156]
- Membrane Proteins [D12.776.543]
- Membrane Glycoproteins [D12.776.543.550]
- Cell Adhesion Molecules [D12.776.543.550.200]
- Cell Adhesion Molecules, Neuronal [D12.776.543.550.200.250]
- Neural Cell Adhesion Molecules [D12.776.543.550.200.250.520]
- CD56 Antigen [D12.776.543.550.200.250.520.156]
- Biological Factors [D23]
- Antigens [D23.050]
- Antigens, Surface [D23.050.301]
- Antigens, Differentiation [D23.050.301.264]
- Antigens, Differentiation, T-Lymphocyte [D23.050.301.264.894]
- CD56 Antigen [D23.050.301.264.894.156]
- Cell Adhesion Molecules [D23.050.301.350]
- Cell Adhesion Molecules, Neuronal [D23.050.301.350.250]
- Neural Cell Adhesion Molecules [D23.050.301.350.250.520]
- CD56 Antigen [D23.050.301.350.250.520.156]
- Biomarkers [D23.101]
- Antigens, Differentiation [D23.101.100]
- Antigens, Differentiation, T-Lymphocyte [D23.101.100.894]
- CD56 Antigen [D23.101.100.894.156]
Below are MeSH descriptors whose meaning is more specific than "CD56 Antigen".
This graph shows the total number of publications written about "CD56 Antigen" by people in this website by year, and whether "CD56 Antigen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2007 | 0 | 1 | 1 |
| 2008 | 0 | 1 | 1 |
| 2014 | 1 | 0 | 1 |
| 2017 | 3 | 8 | 11 |
| 2018 | 5 | 4 | 9 |
| 2019 | 2 | 2 | 4 |
| 2020 | 0 | 2 | 2 |
| 2021 | 0 | 2 | 2 |
To return to the timeline, click here.
Below are the most recent publications written about "CD56 Antigen" by people in Profiles.
-
Downregulation of exhausted cytotoxic T cells in gene expression networks of multisystem inflammatory syndrome in children. Nat Commun. 2021 08 11; 12(1):4854.
-
Restoring NK cells functionality via cytokine activation enhances cetuximab-mediated NK-cell ADCC: A promising therapeutic tool for HCC patients. Mol Immunol. 2021 09; 137:221-227.
-
Can we define CD3+CD56+ cells as NKT cells with impunity? Clin Immunol. 2021 05; 226:108708.
-
NCAM protein and SARS-COV-2 surface proteins: In-silico hypothetical evidence for the immunopathogenesis of Guillain-Barré syndrome. Med Hypotheses. 2020 Dec; 145:110342.
-
Double-bright (CD56bright/CD16bright) natural killer cell adoptive immunotherapy for SARS-CoV-2. Br J Haematol. 2020 09; 190(6):e322-e323.
-
Case Report: Canakinumab for the Treatment of a Patient With COVID-19 Acute Respiratory Distress Syndrome. Front Immunol. 2020; 11:1942.
-
Natural killer cell immunotypes related to COVID-19 disease severity. Sci Immunol. 2020 08 21; 5(50).
-
Lymphocyte subsets with the lowest decline at baseline and the slow lowest rise during recovery in COVID-19 critical illness patients with diabetes mellitus. Diabetes Res Clin Pract. 2020 Sep; 167:108341.
-
Peripheral lymphocyte subset alterations in COVID-19 patients. Int J Lab Hematol. 2020 10; 42(5):e199-e203.
-
The Role of Circulating CD16+CD56+ Natural Killer Cells in the Screening, Diagnosis, and Staging of Colorectal Cancer before Initial Treatment. Dis Markers. 2019; 2019:7152183.